Vital Therapies Announces Second Quarter 2018 Financial Results
August 07, 2018 16:01 ET
|
Vital Therapies, Inc.
SAN DIEGO, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Announces Upcoming Second Quarter Financial Results Conference Call With Webcast
July 31, 2018 16:01 ET
|
Vital Therapies, Inc.
SAN DIEGO, July 31, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Joins the Russell 3000 Index®
June 25, 2018 08:00 ET
|
Vital Therapies, Inc.
SAN DIEGO, June 25, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
June 12, 2018 16:30 ET
|
Vital Therapies, Inc.
SAN DIEGO, June 12, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies to Present at the Jefferies 2018 Global Healthcare Conference
June 07, 2018 08:00 ET
|
Vital Therapies, Inc.
SAN DIEGO, June 07, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Hosting Analyst R&D Day Today
May 24, 2018 08:01 ET
|
Vital Therapies, Inc.
SAN DIEGO, May 24, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies to Host Analyst R&D Day on May 24, 2018
May 11, 2018 08:01 ET
|
Vital Therapies, Inc.
SAN DIEGO, May 11, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Announces First Quarter 2018 Financial Results
May 08, 2018 16:01 ET
|
Vital Therapies, Inc.
- VTL-308 Enrollment Completed with 151 Subjects- On Track for Release of Topline Results in Third Quarter of 2018 SAN DIEGO, May 08, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc....
Vital Therapies Announces Upcoming First Quarter Financial Results Conference Call with Webcast
April 26, 2018 16:05 ET
|
Vital Therapies, Inc.
SAN DIEGO, April 26, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 25, 2018 16:30 ET
|
Vital Therapies, Inc.
SAN DIEGO, April 25, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...